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Abstract
OBJECTIVE: To assess the effect and safety of
Shengxuening (SXN), extract from excrement of
bombyxin, in the treatment of renal anemia, com-
pared to ferrous succinate and ferrous sulfate.
METHODS: According to the participant, interven-
tion, comparison, outcomes, study design (PICOS)
principles, we searched the Chinese Biomedical Lit-
erature Database, China National Knowledge Infra-
structure Database, Chinese Evidence-Based Medi-
cine Database, Wanfang Database (From establish-
ment to December 2014). Two reviewers selected
articles independently according to the inclusion
and exclusion criteria. The quality of included stud-
ies was assessed by using the Cochrane Handbook.
All statistical analyses were conducted by using
Revman (vision 5.2) software.
RESULTS: A total of 14 randomized controlled trials
(RCTs) were enrolled in the review. The results re-
vealed that, when compared with blank group, SXN
significantly improved the hemoglobin (P >) levels
[MD = 6.29, 95% CI (1.65-10.94), P < 0.0008] and al-
bumin (ALB) [MD = 10.98, 95% CI (6.97-14.99), P <
0.00001]. In addition, SXN could significantly in-
crease the P > levels [MD = 10.98, 95% CI (6.97,
14.99), P < 0.00001]. Compared with other oral
medicine SXN could improve the P > levels effec-
tively [MD = 8.49, 95% CI (2.40, 14.58), P = 0.006].
And the subgroups analysis shown that compared
with ferrous-sulfate there were significant differenc-
es [MD = 17.4, 95% CI (15.06, 19.73), P < 0.000 01]
and the result of ferrous-succinate had significant
differences [MD = 5.34, 95% CI (2.12, 8.56), P =
0.001] too. Compared with Intravenous iron
groups, there were statistical differences [MD =
－ 5.04, 95% CI (－ 9.59, － 0.50), P = 0.03]. In the
safety analysis, the rate of adverse reactions in SXN
groups and control groups were 19.3% and 3.7% ,
respectively (P < 0.000 01). Due to our studies were
of poor methodological quality, and the sample
size were small, the results were influenced by bias.
CONCLUSION: Our findings suggest that the SXN
had better effect and was safer in the treatment of
RA than ferrous succinate and ferrous sulfate.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
Renal anemia (RA) is caused by kidney diseases that
lead to the relative or absolute lack of erythropoietin.
In addition, and uremic toxins shortening red cell sur-
vival also contributes to RA.1,2 Anemia induces the de-
velopment of left ventricular hypertrophy and cardio-
vascular disease, which is significantly associated with
mortality and morbidity in End Stage Renal Disease
(ESRD) patients.3-6 The prevalence of anemia in chron-
ic kidney disease (CKD) is 22.0% , 37.0% , 45.4% ,
85.1% and 98.2% respectively from CKD stage 1 to 5
in China.7 Anemia in ESRD patients was mostly treat-
ed with erythropoiesis-stimulating agents (ESA) for
erythropoietin deficiency.8 However, the response to
ESA is sometimes poor due to iron deficiency.9 There-
fore, iron supplementation was widely used in CKD
patients to treat iron deficiency, prevent its develop-
ment in erythropoiesis-stimulating agents (ESA) treat-
ed patients, raise Hb levels in the presence or absence
of ESA treatment, and reduce ESA doses in patients re-
ceiving ESA treatment. Iron therapy could be provided
with oral and intravenous (IV) preparations. IV iron
preparations had been recommended by the National
Kidney Foundation-Kidney Disease Outcomes Quality
Initiative (NKF-KDOQI) for all hemodialysis (HD)
patients for whom the demand for iron cannot be met
by oral therapy alone, and for those on peritoneal dialy-
sis (PD) therapy or who had nondialysisdependent
CKD (NDD-CKD) who remained iron deficient de-
spite attempts at oral supplementation.10 In contrast,
the use of i.v. iron was more costly than oral iron when
accounting for drug cost, administration costs, and in-
direct costs to the patient for time and travel and can
cause rare but serious short-term effects including ana-
phylactic-type reactions, hypotension, and arthralgia.
The frequency of these reactions varies among i.v. iron
products and was highest with high-molecular-weight
products, which had also been associated with
long-term effects such as infection, atherosclerosis, en-
dothelial dysfunction, and renal injury.11,12
Oral iron had been associated with adverse gastrointes-
tinal effects.13 Absorption of oral iron may also be limit-
ed by decreased gastrointestinal absorption due to the
inflammation associated with CKD.14 Accordingly
Shengxuening (SXN) had been widely used in the treat-
ment of RA, after successfully used in the treatment of
various kinds of anemia.15-18The aim of this meta-analy-
sis was therefore to assess the effect and safety of SXN
in the treatment of renal anemia.
METHODS
Criteria for considering studies for this review
Types of studies: randomized controlled trials (RCTs),
without language restriction; types of participants: Pa-
tients met the diagnostic criteria12 for RA; types of inter-
ventions: SXN was used in treatment groups; types of
outcome measures: (a) primary outcomes: Hemoglobin
(HB), Serum transferrin saturation (TSAT), Hemato-
crit (Hct), serum iron (SI), adverse events; (b) second-
ary outcomes: hypersensitive c-reactive protein
(Hs-crp), albumin (ALB). Animal research, patients
with other chronic disease which influences the iron
metabolism were excluded.
Search methods for identification of studies
(a) Electronic searches: Two authors independently
searched the databases as follows: Chinese Biomedical
Literature Database, China National Knowledge Infra-
structure Database, Chinese Evidence-Based Medicine
Database, Wanfang Database (From establishment to
December 2014). We used the keywords in the search
according to the PICOS principles. The MeSH of
chronic renal insufficiency, chronic renal failure,
end-stage renal disease, toxuria, chronic kidney disease,
hemodialysis, peritoneal dialysis, renal anemia,anemia,
Shengxuening and randomized was used in search strat-
egy. The search strategy of China National Knowledge
Infrastructure Database was as follows: #1 chronic re-
nal insufficiency; #2 chronic renal failure; #3 end-
stage renal disease; #4 toxuria; #5 chronic kidney dis-
ease; #6 hemodialysis; #7 peritoneal dialysis; #8 #1OR#
2OR#3OR#4OR#5OR#6OR#7; #9 renal anemia; #
10 anemia; #11 #9OR#10; #12 randomized; #13 #
8AND##11AND#12. (b) Searching other resources:
hand searching the reference lists of relevant papers
and literature reviews. (c) Gray literature: searching
the unpublished literature and contacting the author
if necessary.
Data collection
Two reviewers (Zhang Lei and Zhang Wenjin) selected
articles independently for inclusion, evaluated the
methodological quality and extracted data. Disagree-
ment between reviewers was resolved through discus-
sion, and additional information was sought from trial
authors when necessary.
Risk of bias assessment
The Cochrane Colaboration's risk of bias list was taken
as follows: (a) random sequence generation; (b) alloca-
tion concealment; (c) blinding of participants and per-
sonnel; (d) blinding of outcome assessment; (e) incom-
plete outcome data; (f ) selective reporting; (g) other bi-
ases. According to these six projects two authors who
had been trained, evaluated the literatures independent-
ly. Three categories of "yes" (low risk of bias), "no"
(high risk of bias), or "not clear" (the risk of bias can-
not be determined) were used in the assessment.
Statistical analysis
Statistical analysis was performed using Review Manag-
er Version 5.2 software (Copenhagen the Nordic Co-
chrane center the Cochrane collaboration 2012). The
risk ratio (RR) with 95% confidence interval (CI) was
589
JTCM |www. journaltcm. com October 15, 2016 |Volume 36 | Issue 5 |
Zhang L et al. / Systematic Review
calculated for binary data, and the mean difference
with 95% CI for continuous variables. Random and
fixed-effects models were used to calculate the com-
bined outcomes of both binary and continuous data.
Heterogeneity was assessed based on the χ2 test. A ran-
dom effects model was used for meta-analysis where
there was statistical heterogeneity (P < 0.10) and a
fixed effects model where there was not statistical het-
erogeneity (P ≥ 0.10). Subgroup analysis was conduct-
ed with the reason of heterogeneity.
RESULTS
Literature search and characteristics of the included
trials
Literature search identified 75 studies. Fifty-five stud-
ies were excluded by reading the title and abstract. A to-
tal of 14 studies were eligible (Figure 1). A total of 747
participants were included in the 14 studies. Totally
373 participants were in treatment group, and 374 in
control group (414 males, 333 females) (Table 1).
Methodological quality assessment
We used the risk of bias assessment tool in the Co-
chrane Handbook to assess the methodological quality
of included studies. The results of the methodological
qualities of trials were shown in Figures 2 and 3.
Statistical analysis
Table 2 presents a summary of the results of the me-
ta-analysis. Analysis revealed that SXN statistically sig-
nificantly improved the HB [MD = 6.29, 90% CI
(1.65-10.94), P < 0.0008] (Figure 4) and ALB [MD =
1.37, 90% CI (－2.04, －4.78), P < 0.000 01] only
(Figure 5). No significant effect was found for TSAT,
Hct, SI and Hs-crp. According to the studies we did
some subgroups analysis on HB. Blank control were
used in three articles.25-27There was no statistical hetero-
geneity (I 2 = 0%) among those studies, the fixed effect
model was used for meta-analysis. The results (Figure
6) showed that there were significant differences
[MD = 10.98, 95% CI (6.97, 14.99), P < 0.000 01],
which indicated that the SXN group could increase the
HB levels compared with blank group. Eight studies19-24,
28,30 used oral iron in control groups, which had statisti-
cal heterogeneity (I 2 = 94%), the random effect model
was used for Meta-analysis. The results (Figure 7)
showed that there were significant differences [MD =
8.49, 95% CI (2.40, 14.58), P = 0.006], which indicat-
ed that compared with other oral medicine, SXN
could improve the HB levels effectively. What's more,
in oral groups there were three studies19,20,22 using fer-
rous-sulfate as placebo. Also ferrous-succinate was used
in three studies.21,23,24 While, only one study took fer-
rous-vitamin-complex sustained-release28 and tablet-
spolysaccharide-iron30 in control group, respectively.
Naturally, the meta-analysis of SXN vs ferrous-sulfate
and SXN vs ferrous-succinate were be done. There was
no statistical heterogeneity (I 2 = 0%) in both analyses,
compared with ferrous-sulfate differences were signifi-
cant [MD = 17.4, 95% CI (15.06, 19.73), P < 0.000
01] (Figure 8), and the result of ferrous-succinate had
significant differences [MD = 5.34, 95% CI (2.12,
8.56), P = 0.001] too (Figure 9). Intravenous iron was
used for treatment of iron deficiency in three stidues29,
31-32as placebo.There was no statistical heterogeneity (I 2 =
17%) among the three studies, the fixed effect model
was used for meta-analysis. The results (Figure 10)
showed that differences were statistically significant
[MD =－5.04, 95% CI (－9.59,－0.50), P = 0.03].
Studies through the database search
(n = 75)
Studies through other resources
(n = 0)
Exclude repeating studies
（n = 20）
Studies for reading the full text
（n = 55）
Exclude studies not meet the criteria
（n = 31）
Studies for final Meta analysis（n = 14）
SXN group vsblank group
(n = 3)
SXN group vsWestern Medicine group
(n = 11)
Figure 1 Flow chart of article screening and selection process
SXN: Shengxuening.
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Adverse events
Adverse events were
reported in 13 stud-
ies,19-25,27-32 which was
mainly manifested as
varying degrees of di-
gestive discomfort,
including nausea,
vomit, bloating and
acid regurgitation. A
total of 62 cases hap-
pened in control
groups, while only
12 cases reported in
SXN groups. The
rate of adverse reac-
tions was 19.3% and
3.7% respectively.
Meta analysis
showed that there
had the statistical ho-
mogeneity (χ2 =
11.12, P = 0.43, I 2 =
1% ), and the fixed
effect model was
used, the results (Fig-
ure 11) showed that
the difference was
statistically signifi-
cant (P < 0.000 01).
DISCUSSION
In this review, the
major findings are:
(a) SXN impactful
increase the levels of
HB for RA patients
base on the treat-
ment of erythropoie-
tin (EPO); (b) SXN
significant promotes
RA patient's HB lev-
el compared with fer-
rous-sulfate and fer-
rous-succinate with
fewer adverse effects;
(c) SXN improves
patient's nutritional
status and does not
add the inflamma-
tion risk; (d) SXN
has higher security
than other medicine
with less adverse
events.
SXN is extractedTab
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Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
Figures 2 Bar graph showing risk of bias
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
LiaoXY2012 29
LiHBetal2010 25
LiuF2013 23
LongLetal2012 22
LuJB2013 32
MaXH
etal2014 19
MiCX2013 21
TangCY2011 26
TangJPetal2013 20
WangLetal2012 31
WangW
Yetal2013 28
XuQH
2012 27
YangYetal2011 30
ZhaoXJetal2012 24
Figures 3 summary of risk of bias
Table 2 Summary of the results of the meta-analysis for all outcomes
Outcome
HB
HCT
SI
TSAT
ALB
Hs-CRP
No. of studies
14
12
12
12
3
2
No. of participants
747
623
641
641
244
184
Mean difference
(95% confidence interval)
6.29 [1.65, 10.94]
2.71 [－0.94, 6.36]
44.86 [－6.59, 96.31]
3.31－1.25, 7.87]
2.74 [1.17, 3.11]
0.11 [－0.84, 0.62]
P value
0.008
0.15
0.09
0.16
< 0.001
0.77
Notes: HB: hemoglobin; Hct: hematocrit; TSAT: serum transferrin saturation; ALB: albumin; SI: serum iron; Hs-crp: hypersensitive c-re-
active protein.
Figures 4 Comparison of Hemoglobin of Shengxuening groups vs control groups
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from the excrement of bombyxin. The study35 showed
that the main ingredient in it was ferrous derivative,
which was mainly composed of Fe chlorin p6, Fe chlo-
rin e6 and Fe isochlorin e4. A single-center research36
found that 73.6% CKD patients had abnormal upper
gastrointestinal endoscopic findings. The gastroduode-
nal lesion observed was hemorrhagic gastritis (31.5%),
followed by hemorrhagic gastroduodenitis (26.3% ),
gastricnodular gastritis (10.5%), and polyps (10.5%).
However, oral iron is mainly absorbed in the duode-
Figures 5 Forest plot of meta-analysis results of albumin
Figures 7 Comparison of hemoglobin of Shengxuening groups vs oral groups
Figures 8 Comparison of hemoglobin of Shengxuening groups vs sulfate groups
Figures 9 Comparison of hemoglobin of Shengxuening groups vs succinate groups
Figures 10 Comparison of hemoglobin of Shengxuening groups vs intravenous groups
Figures 6 Comparison of hemoglobin of Shengxuening groups vs blank groups
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num and upper jejunm mucosa with an acid environ-
ment,37,38 which would cause gastrointestinal reaction.
While, chlorophyll which is contained in SXN has the
same structure with as heme in human body, so it can
directly compound hemoglobin, which increases the
bioavailability.39 The organic hematin chloride in SXN
and the human's haematoporphyrin are similar, which
can be immediate absorbed by the intestinal mucosal
cells of the gastric mucosa with less irritation that in-
crease the absorption of protein.40
Several limitations in our analysis merit consideration.
First, all included studies were from the same country.
A publication bias was inevitable. Second, the power of
our analysis is limited by the heterogeneity among the
outcomes, even though subgroups analysis were taken,
we could not analyze the heterogeneity in HCT, SI and
TSAT, which may add the risk of bias. Third, due to
the sample size was small. The subgroup analysis of the
hemodialysis patients and non dialysis patients had not
been done, which would increase the limitations of our
results.
According to our analysis, SXN had better effect and
was safer in the treatment of RA than ferrous succinate
and ferrous sulfate. But the findings should be further
confirmed with rigorous, large sample size, multicenter
studies.
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